Fasinumab
Dyspepsia
Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Dyspepsia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lucoridalines Seoul National University Hospital | Phase 4 | BB |
Tannic Acid Hospital Infantil Cândido Fontoura | Phase 3 | BB |
Lidocaine Hospital Infantil Cândido Fontoura | Phase 3 | BB |
N-(P-(2-(Dimethylamino)Ethoxy)Benzyl)Veratramide Abbott | Phase 3 | BB |
Same molecule, other indications
Fasinumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →